- Home
- SRRK vs FROG Comparison
SRRK vs FROG Comparison
Compare SRRK & FROG Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SRRK
- FROG
- Stock Information
- Founded
- SRRK 2012
- FROG 2008
- Country
- SRRK United States
- FROG United States
- Employees
- SRRK N/A
- FROG N/A
- Industry
- SRRK Biotechnology: Biological Products (No Diagnostic Substances)
- FROG Computer Software: Prepackaged Software
- Sector
- SRRK Health Care
- FROG Technology
- Exchange
- SRRK Nasdaq
- FROG Nasdaq
- Market Cap
- SRRK 4.2B
- FROG 3.6B
- IPO Year
- SRRK 2018
- FROG 2020
- Fundamental
- Price
- SRRK $43.35
- FROG $32.17
- Analyst Decision
- SRRK Strong Buy
- FROG Strong Buy
- Analyst Count
- SRRK 7
- FROG 18
- Target Price
- SRRK $40.43
- FROG $36.29
- AVG Volume (30 Days)
- SRRK 1.2M
- FROG 833.0K
- Earning Date
- SRRK 11-12-2024
- FROG 02-12-2025
- Dividend Yield
- SRRK N/A
- FROG N/A
- EPS Growth
- SRRK N/A
- FROG N/A
- EPS
- SRRK N/A
- FROG N/A
- Revenue
- SRRK N/A
- FROG $409,670,000.00
- Revenue This Year
- SRRK N/A
- FROG $24.37
- Revenue Next Year
- SRRK N/A
- FROG $17.11
- P/E Ratio
- SRRK N/A
- FROG N/A
- Revenue Growth
- SRRK N/A
- FROG 24.45
- 52 Week Low
- SRRK $6.76
- FROG $22.91
- 52 Week High
- SRRK $46.19
- FROG $48.81
- Technical
- Relative Strength Index (RSI)
- SRRK 69.26
- FROG 57.31
- Support Level
- SRRK $40.95
- FROG $29.37
- Resistance Level
- SRRK $44.22
- FROG $32.15
- Average True Range (ATR)
- SRRK 2.57
- FROG 0.91
- MACD
- SRRK -0.12
- FROG 0.01
- Stochastic Oscillator
- SRRK 73.14
- FROG 86.69
About SRRK Scholar Rock Holding Corporation
Scholar Rock Holding Corp is a biopharmaceutical company. It is engaged in the discovery and development of innovative medicines for the treatment of serious diseases including neuromuscular disorders, cancer, fibrosis, and anemia. Geographically, the company operates in the United States. The company's product candidate is Apitegroma which is a selective, fully human, monoclonal antibody, with a mechanism of action that results in inhibition of the activation of the growth factor, myostatin, in skeletal muscle. Its other product comprises SRK-181, an inhibitor of the activation of latent transforming growth factor beta-1 ("TGFβ1"), for the treatment of cancers that are resistant to anti-PD-(L)1 antibody therapies.
About FROG JFrog Ltd.
JFrog Ltd provides an end-to-end, hybrid, universal DevOps Platform that powers and controls the software supply chain, enabling organizations to continuously and securely deliver software updates across any system. Its product portfolio includes JFrog Artifactory; JFrog Pipelines; JFrog Xray; JFrog Distribution; JFrog Artifactory Edge; JFrog Mission Control and JFrog Insight. Geographically, it derives a majority of revenue from Israel and also has its presence in United States, India and other regions.